Transforming genomic insights into actionable health solutions through advanced R&D and commercialization
Founded in 2017, Actionable Genomics is an Australian company at the forefront of biotechnology innovation. We focus on R&D and commercialization of cutting-edge technologies that bridge the gap between genomic science and practical health applications. Operating as an intellectual property bank, Actionable Genomics generates revenue through strategic licensing of its IP portfolio to associated and affiliated companies, enabling rapid deployment of innovations while maintaining core research capabilities.
Pioneering solutions across multiple domains of biotechnology
Developing next-generation peptide synthesis technologies for therapeutic applications and research purposes.
Leveraging artificial intelligence to unlock insights from complex biological data and accelerate discovery.
Applications for interpreting genetic, epigenetic, and blood biomarkers to provide comprehensive health insights.
Smart medical practice management software powered by ambient intelligence for enhanced healthcare delivery.
Non-invasive DNA collection devices for epidermal skin cell specimens, featuring pressure-sensitive adhesive technology for genetic analysis applications.
Innovative peptide therapies, stem cell treatments, and pharmaceutical repurposing to decelerate aging and extend healthspan in companion animals.
Using artificial intelligence to maximize the interpretive potential of mass spectrometric data for enhanced molecular identification and quantification.
Commercializing innovative biomarkers using mitochondrial copy number quantification and miRNA detection for disease diagnosis and monitoring.
Extending biological half-life of therapeutic peptides through advanced modification strategies for improved clinical efficacy and patient compliance.
At Actionable Genomics, we combine cutting-edge technology with deep scientific expertise to deliver innovative solutions that address real-world health challenges.
Advanced analytics and AI to extract meaningful patterns from complex biological data
Combining genomics, epigenetics, and biomarkers for comprehensive health understanding
Exploring the opportunities that are found at the intersection of domains
Translating research into actionable solutions for healthcare providers and patients
Founded in 2017, Actionable Genomics operates at the frontier where computational biology meets therapeutic innovation. We've built a vertically integrated platform that transforms aging from an abstract concept into quantifiable, modifiable biology—turning years of research into actionable interventions that extend human healthspan.
Our intellectual property portfolio spans the complete value chain: from AI-driven biomarker discovery and epigenetic profiling to peptide therapeutics and non-invasive diagnostic devices. By maintaining control across discovery, validation, and commercialization, we accelerate the translation of breakthrough science into clinical reality—delivering precision interventions that target the root mechanisms of aging rather than its symptoms.
Our core strength lies in the seamless integration of our in-house molecular biology and chemistry laboratories with advanced computational resources. This unique combination enables rapid iteration from computational prediction to wet-lab validation, accelerating discovery cycles and ensuring that our theoretical insights translate into tangible therapeutic solutions. Our laboratories are equipped for everything from peptide synthesis and mass spectrometry to cell culture and epigenetic analysis, while our computational infrastructure powers AI-driven drug discovery and multi-omics data integration.
To redefine human aging—from an inevitable decline into a measurable and modifiable biological process—establishing extended healthspan as the new standard of care.
To create the leading platform that deciphers individual aging trajectories and translates them into actionable interventions. By uniting computational discovery, biological validation, and clinical translation, we deliver a seamless pipeline—from advanced biomarker analytics to next-generation therapeutics such as peptides—under one roof.
Strategic relationships translating our IP into market-ready solutions
Personalized genetic health and performance optimization platform that integrates 1M genetic biomarkers, mitochondrial copy number, blood testing, sleep and activity data. MyGene's AI-powered gene.codes platform delivers precision health programs and whole-system intelligence for biological aging assessment and intervention.
State-of-the-art peptide synthesis laboratory advancing therapeutic peptide R&D. Provides custom synthesis, quality assurance testing, and rapid development services while working toward TGA GMP accreditation for clinical-grade manufacturing.
Precision medicine through targeted molecular therapies and telehealth services. Bridges the gap between advanced diagnostics and clinical intervention, delivering personalized treatment pathways based on molecular profiling.
Interested in our research, technologies, or partnership opportunities? We'd love to hear from you.